GTHX G1 Therapeutics
- 4.770
- -0.210-4.22%
G1 Therapeutics News
What's Going On With G1 Therapeutics Stock?
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer. What To Know:According to a report from Seeking Alpha, G1 Therapeutics has receive
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmbecta (NASDAQ:EMBC) shares increased by 37.7% to $14.14 during Thursday's regular session. The company's market cap stands at $814.1 million. As per the press release, Q2 earnings came out to
Express News | G1 Therapeutics Shares Are Trading Higher Amid M&A Blog Speculation of a Takeover Offer
G1 Therapeutics Jumps Amid Takeover Speculation
Express News | Watching G1 Therapeutics; Traders Circulate M&A Blog Suggesting Company Rumored To Have A CVR Aspect That Could Value The Company At Between $12-$14/Share
G1 Therapeutics, Inc. (NASDAQ:GTHX) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Express News | HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $9 Price Target
Optimistic Buy Rating for G1 Therapeutics Amidst Solid Financial Footing and Cosela's Market Expansion
Express News | G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Evaluating G1 Therapeutics: Insights From 5 Financial Analysts
Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on G1 Therapeutics (NASDAQ:GTHX) in the last three months.The following table summarizes their rece
Earnings Call Summary | G1 Therapeutics(GTHX.US) Q1 2024 Earnings Conference
The following is a summary of the G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript:Financial Performance:G1 Therapeutics reported a 34% increase in COSELA's net sales, amounting to $14.1
Express News | Needham Reiterates Buy on G1 Therapeutics, Maintains $12 Price Target
G1 Therapeutics: A Buy Rating on Promising Trials and Robust Financial Outlook
G1 Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/01/2024 219.15% Needham → $12 Reiterates Buy → Buy 04/12/2024 219.15% Needham → $12 Reiterates Buy → Bu
G1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment With Analyst Revenue Projections
Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, Vs. Street Est of $15.1M
06:40 AM EDT, 05/01/2024 (MT Newswires) -- Earnings Flash (GTHX) G1 THERAPEUTICS Reports Q1 Revenue $14.5M, vs. Street Est of $15.1M
G1 Therapeutics Q1 2024 GAAP EPS $(0.20), Inline, Sales $14.476M Miss $15.259M Estimate
G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 62.26 percent increase over losses of $(0.53) per share from the same p
Express News | G1 Therapeutics Inc: Reaffirmed Its Full Year 2024 Financial Guidance
Express News | G1 Therapeutics Inc: Reaffirmed 2024 Net Cosela Revenue Guidance of $60 to $70 Mln
Express News | G1 Therapeutics Inc: Cash Runway Expected to Extend Into Q3 of 2025
Analysis
Price Target
No Data
